Q BioMed Inc.
Q BioMed Inc. (QBIO): 29 pipeline candidates · ~1 mo cash runway · 14 clinical trials. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
1.1 months
D/E -1.54 · 0% dilution
Lead: Phase 3
29 candidates
N/A
N/A
A transparent, data-derived signal for Q BioMed Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$15K
Cash
$50K
Quarterly Burn
$138K
Runway
1.1 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (29 candidates)
| Drug | Phase |
|---|---|
| bionetide | Phase 3 |
| cln-418 | Phase 1 |
| hbm1020 | Phase 1 |
| hbm4003 | Phase 1 |
| hbm9036 0.25% | Phase 3 |
| hbm9161 | Phase 3 |
| hbm9161 dose a | Phase 3 |
| hbm9161 dose b | Phase 3 |
| hbm9378 | Phase 1 |
| hydroxychloroquine | Phase 2 |
Showing 10 of 29 candidates. Sign up for full pipeline.
Frequently asked questions
How many drug candidates are in Q BioMed Inc.'s pipeline?
Q BioMed Inc. (QBIO) has 29 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Q BioMed Inc.'s lead drug candidate?
Q BioMed Inc.'s most advanced tracked candidate is bionetide (Phase 3) for Rett Syndrome.
What is Q BioMed Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Q BioMed Inc. has approximately 1.1 months of cash runway.
What is Q BioMed Inc.'s market capitalization?
Q BioMed Inc.'s market capitalization is approximately $15K.
Who is the CEO of Q BioMed Inc.?
Mr. Denis D. Corin is the chief executive officer of Q BioMed Inc. (QBIO).
Get the full picture on Q BioMed Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.